Nowrousian M R, Schmidt C G
Cancer Chemother Pharmacol. 1982;9(1):6-9. doi: 10.1007/BF00296752.
In two studies, haematopoietic late effects of prolonged bleomycin treatment were evaluated in mice given serial injections of 21 mg bleomycin/m2 weekly for 31 and 44 weeks, respectively. Femoral bone marrow cellularity measured at 43, 45, and 49 weeks after discontinuation of the drug in the first and after 20 weeks in the second study was found to be significantly (P less than 0.05) lower in the treated mice than in the controls. CFU-S, BFU-E, and CFU-C contents were also reduced in the treated bone marrow, but with the exception of CFU-S in the second study, differences from control values were not significant. Additional long-term bone marrow cultures performed in the second study revealed no marked changes in the marrow proliferative activity and the self-renewal of stem cells to explain the reduced marrow cellularity and stem cell content. These last findings might, therefore, be due to a decrease in femoral size with less marrow content in the treated mice, since measurements of the tibial weights in both groups showed that the bones in the treated animals were significantly (P less than 0.05) lighter than those in the controls.
在两项研究中,分别对每周接受21mg博来霉素/m²连续注射31周和44周的小鼠进行了长期博来霉素治疗的造血晚期效应评估。在第一项研究停药后43周、45周和49周以及第二项研究停药后20周时,测量发现治疗组小鼠的股骨骨髓细胞密度显著低于对照组(P<0.05)。治疗组骨髓中的CFU-S、BFU-E和CFU-C含量也有所降低,但除第二项研究中的CFU-S外,与对照值的差异不显著。第二项研究中进行的额外长期骨髓培养显示,骨髓增殖活性和干细胞自我更新没有明显变化,无法解释骨髓细胞密度和干细胞含量的降低。因此,这些最终发现可能是由于治疗组小鼠股骨尺寸减小,骨髓含量减少,因为两组胫骨重量测量显示,治疗组动物的骨骼明显比对照组轻(P<0.05)。